Skip to main content
Year archive

Heidelberg Pharma AG — 2025 filings

All 41 regulatory filings released by Heidelberg Pharma AG (HPHA) in 2025, sourced directly from the official regulator.

41 Filings
2025 Period
2025 filings (41)
Filing Released Lang
Heidelberg Pharma: Letter from the CEO
Legal Proceedings Report
2025-12-17 English
Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Board/Management Information
2025-11-24 English
Heidelberg Pharmas Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Regulatory Filings
2025-11-06 English
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Regulatory Filings
2025-11-03 English
Heidelberg Pharmas Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Regulatory Filings
2025-10-23 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-10-13 English
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Interim / Quarterly Report 9M 2025
2025-10-09 English
Quartalsfinanzbericht
Interim / Quarterly Report 9M 2025
2025-10-09 German
Q3 statement / Q3 financial report 2024/2025
Interim / Quarterly Report 9M 2025
2025-10-09 English
Heidelberg Pharma AG Announces Updated Guidance
Earnings Release FY 2025
2025-10-06 English
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Regulatory Filings
2025-09-25 English
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Regulatory Filings
2025-09-04 English
Heidelberg Pharmas Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Regulatory Filings
2025-08-28 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-07-31 English
Datum:31.07.2025
Audit Report / Information FY 2024
2025-07-31 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
AGM Information
2025-07-31 German
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for employees and me
Director's Dealing
2025-07-24 English
Datum:23.07.2025
Audit Report / Information FY 2024
2025-07-23 German
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Earnings Release H1 2025
2025-07-10 English
Half-yearly financial report 2024/2025
Interim / Quarterly Report H1 2025
2025-07-10 English
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Regulatory Filings
2025-05-27 English
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
AGM Information
2025-05-16 English
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
Regulatory Filings
2025-05-14 English
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Interim / Quarterly Report Q1 2025
2025-04-24 English
Q1 statement / Q1 financial report 2024/2025
Earnings Release Q1 2025
2025-04-24 English
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 15.05.2025 in Ladenburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2025-04-05 German
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements
2025-04-03 German
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Regulatory Filings
2025-03-26 English
Annual financial report 2023/2024
Annual Report FY 2024
2025-03-22 English
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Earnings Release FY 2024
2025-03-21 English
Annual financial report 2023/2024
Annual Report FY 2024
2025-03-21 English
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
Capital/Financing Update
2025-03-14 English
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
Capital/Financing Update
2025-03-13 English
Report Publication Announcement 2025
Report Publication Announcement
2025-01-24 English
Report Publication Announcement 2025
Report Publication Announcement
2025-01-23 English
Hinweis auf Konzernabschluss vom 01.12.2023 bis zum 30.11.2024
Report Publication Announcement
2025-01-23 German
Hinweis auf Konzernabschluss vom 01.12.2023 bis zum 30.11.2024
Report Publication Announcement
2025-01-23 German
Hinweis auf Halbjahresfinanzbericht vom 01.12.2024 bis zum 31.05.2025
Report Publication Announcement
2025-01-23 German
Hinweis auf Jahresfinanzbericht vom 01.12.2023 bis zum 30.11.2024
Report Publication Announcement
2025-01-23 German
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Legal Proceedings Report
2025-01-14 English
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Regulatory Filings
2025-01-13 English